Omeprazole: a new drug for the treatment of acid-peptic diseases
Donald G. Vidt, MD
Alan Bakst, PharmD
Gary W. Falk, MDAddress reprint requests to G.W.F., Department of Gastroenterology, The Cleveland Clinic Foundation, One Clinic Center, 9500 Euclid Avenue, Cleveland OH 44195.
Omeprazole is the first of a new class of gastric antisecretory drugs, proton pump inhibitors. It inhibits the H+,K+-adenosinetriphosphatase enzyme of the gastric parietal cell, resulting in potent, long-lasting suppression of basal and stimulated acid secretion. The drug is currently approved for treatment of gastroesophageal reflux disease and Zollinger-Ellison syndrome. In clinical trials, treatment with omeprazole results in rapid healing of duodenal ulcers; it is also effective in treating gastric ulcer disease. It is uniformly well tolerated without significant adverse effects, although animal studies linked profound long-term suppression of gastric acid secretion with the development of gastric carcinoids. Potential future uses include the prophylaxis of ulceration secondary to stress or use of nonsteroidal anti-inflammatory drugs, and the prophylaxis of recurrent peptic ulcer disease.